Today: 22 December 2025
Subscribe
Browse Tag

Keytruda

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

December 18, 2025 — Merck & Company, Inc. (NYSE: MRK) is back in the spotlight for investors today as three threads converge: a fresh Wall Street upgrade tied to Merck’s post‑Keytruda strategy, a potentially meaningful FDA fast‑track development for two
18 December 2025
 ·  ·  ·  · 
Merck (MRK) Stock After Hours: FDA Fast‑Track Vouchers, Keytruda‑Padcev Trial Win, and What to Watch Before the Dec. 18 Market Open

Merck (MRK) Stock After Hours: FDA Fast‑Track Vouchers, Keytruda‑Padcev Trial Win, and What to Watch Before the Dec. 18 Market Open

Merck & Co., Inc. (NYSE: MRK) finished regular trading on Wednesday, Dec. 17, 2025 in positive territory, then held near the $99 level in extended hours as investors weighed two major pipeline headlines—one before the opening bell and another after
18 December 2025
 ·  ·  ·  ·  · 
Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck & Co., Inc. (NYSE: MRK) stock was among the biggest drags on the Dow Jones Industrial Average in Tuesday’s session (December 16, 2025), with shares trading lower as investors weighed broad market pressure alongside a fast-moving set of company-specific
16 December 2025
 ·  ·  ·  ·  · 
Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck & Co., Inc. (NYSE: MRK) heads into Monday’s U.S. session (December 15, 2025) with investors juggling a mix of near-term headlines and long-term franchise questions: a fresh dividend “reset” that makes Dec. 15 an important calendar day, ongoing scrutiny
14 December 2025
 ·  ·  ·  ·  · 
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in
12 December 2025
 ·  ·  ·  ·  · 
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt
7 December 2025
 ·  ·  ·  ·  · 
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As
29 November 2025
 ·  ·  ·  ·  · 
1 2
Go toTop